Takeda Historical Balance Sheet

TAK Stock

USD 13.38 0.05 0.38%

Trend analysis of Takeda Pharmaceutical Co balance sheet accounts such as Total Current Liabilities of 2.4 T, Total Stockholder Equity of 7.6 T, Property Plant And Equipment Net of 2.1 T or Current Deferred Revenue of 120.1 B provides information on Takeda Pharmaceutical's total assets, liabilities, and equity, which is the actual value of Takeda Pharmaceutical to its prevalent stockholders. By breaking down trends over time using Takeda Pharmaceutical balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Takeda Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Takeda Pharmaceutical is a good buy for the upcoming year.

Takeda Pharmaceutical Inventory

1.27 Trillion

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Takeda Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Takeda Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Takeda Pharmaceutical Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Takeda Pharmaceutical and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Takeda currently owns. An asset can also be divided into two categories, current and non-current.

Takeda Pharmaceutical Balance Sheet Chart

At this time, Takeda Pharmaceutical's Property Plant And Equipment Net is quite stable compared to the past year. Net Debt is expected to rise to about 5.5 T this year, although the value of Accounts Payable will most likely fall to about 187 B.

Total Assets Common Stock Shares Outstanding Short Long Term Debt Total Other Current Liab Total Permanent Equity Property Plant Equipment

Add Fundamental

Total Assets

Total assets refers to the total amount of Takeda Pharmaceutical assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Takeda Pharmaceutical books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most accounts from Takeda Pharmaceutical's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Takeda Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	1.4T	1.5T	1.1T	1.2T
Short and Long Term Debt Total	4.3T	4.4T	5.5T	5.7T

Other Current Liab Short Long Term Debt Total

Takeda Pharmaceutical balance sheet Correlations

	Total Assets	Common Stock Shares Outstanding	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		-0.14	0.99	0.93	0.96	0.98	0.98	-0.08	0.98	-0.31	0.69	0.13	1.0	0.49	0.32	0.81	0.99	-0.1	0.98	0.98	0.91	0.95	0.99	0.9	0.91	0.62
Common Stock Shares Outstanding	-0.14		-0.05	-0.06	-0.07	-0.25	-0.29	-0.1	-0.09	-0.11	-0.14	0.4	-0.16	-0.49	0.08	0.05	-0.12	-0.23	-0.04	-0.16	-0.38	-0.01	-0.05	-0.38	0.19	0.26
Short Long Term Debt Total	0.99	-0.05		0.9	0.96	0.94	0.95	-0.05	0.99	-0.35	0.68	0.14	0.99	0.46	0.31	0.82	0.99	-0.13	0.99	0.96	0.85	0.95	0.99	0.84	0.92	0.68
Other Current Liab	0.93	-0.06	0.9		0.91	0.9	0.9	-0.17	0.87	-0.32	0.69	0.29	0.93	0.27	0.38	0.76	0.92	-0.25	0.91	0.89	0.89	0.89	0.92	0.84	0.88	0.5
Total Current Liabilities	0.96	-0.07	0.96	0.91		0.92	0.93	-0.15	0.96	-0.33	0.74	0.1	0.96	0.39	0.2	0.77	0.95	-0.21	0.94	0.95	0.85	0.88	0.97	0.85	0.88	0.75
Total Stockholder Equity	0.98	-0.25	0.94	0.9	0.92		1.0	-0.18	0.95	-0.29	0.64	0.0	0.98	0.62	0.26	0.72	0.97	0.03	0.92	0.99	0.94	0.91	0.93	0.97	0.83	0.54
Property Plant And Equipment Net	0.98	-0.29	0.95	0.9	0.93	1.0		-0.14	0.96	-0.31	0.68	0.0	0.98	0.61	0.25	0.74	0.97	0.01	0.93	0.98	0.95	0.91	0.94	0.96	0.82	0.53
Current Deferred Revenue	-0.08	-0.1	-0.05	-0.17	-0.15	-0.18	-0.14		-0.09	0.14	-0.05	0.36	-0.09	-0.18	0.28	0.3	-0.05	-0.12	0.04	-0.2	-0.06	-0.06	-0.01	-0.31	0.06	-0.29
Net Debt	0.98	-0.09	0.99	0.87	0.96	0.95	0.96	-0.09		-0.34	0.68	0.04	0.98	0.53	0.23	0.79	0.98	-0.08	0.97	0.97	0.86	0.93	0.98	0.87	0.88	0.7
Retained Earnings	-0.31	-0.11	-0.35	-0.32	-0.33	-0.29	-0.31	0.14	-0.34		-0.37	-0.15	-0.32	-0.02	-0.2	0.04	-0.38	0.19	-0.32	-0.32	-0.14	-0.45	-0.32	-0.31	-0.23	-0.2
Accounts Payable	0.69	-0.14	0.68	0.69	0.74	0.64	0.68	-0.05	0.68	-0.37		0.08	0.7	0.12	-0.02	0.61	0.68	-0.15	0.69	0.63	0.61	0.6	0.71	0.62	0.63	0.43
Cash	0.13	0.4	0.14	0.29	0.1	0.0	0.0	0.36	0.04	-0.15	0.08		0.1	-0.61	0.8	0.36	0.16	-0.55	0.25	-0.01	-0.02	0.23	0.21	-0.15	0.43	-0.08
Non Current Assets Total	1.0	-0.16	0.99	0.93	0.96	0.98	0.98	-0.09	0.98	-0.32	0.7	0.1		0.5	0.29	0.8	0.99	-0.09	0.98	0.98	0.92	0.94	0.98	0.91	0.89	0.61
Non Currrent Assets Other	0.49	-0.49	0.46	0.27	0.39	0.62	0.61	-0.18	0.53	-0.02	0.12	-0.61	0.5		-0.13	0.19	0.47	0.63	0.38	0.61	0.58	0.4	0.39	0.68	0.22	0.23
Cash And Short Term Investments	0.32	0.08	0.31	0.38	0.2	0.26	0.25	0.28	0.23	-0.2	-0.02	0.8	0.29	-0.13		0.33	0.34	-0.15	0.38	0.24	0.2	0.37	0.34	0.14	0.48	-0.09
Net Receivables	0.81	0.05	0.82	0.76	0.77	0.72	0.74	0.3	0.79	0.04	0.61	0.36	0.8	0.19	0.33		0.81	-0.22	0.87	0.72	0.75	0.77	0.86	0.57	0.9	0.47
Common Stock Total Equity	0.99	-0.12	0.99	0.92	0.95	0.97	0.97	-0.05	0.98	-0.38	0.68	0.16	0.99	0.47	0.34	0.81		-0.12	0.98	0.97	0.9	0.97	0.99	0.89	0.9	0.58
Short Term Investments	-0.1	-0.23	-0.13	-0.25	-0.21	0.03	0.01	-0.12	-0.08	0.19	-0.15	-0.55	-0.09	0.63	-0.15	-0.22	-0.12		-0.18	0.01	0.01	-0.19	-0.19	0.11	-0.18	-0.23
Non Current Liabilities Total	0.98	-0.04	0.99	0.91	0.94	0.92	0.93	0.04	0.97	-0.32	0.69	0.25	0.98	0.38	0.38	0.87	0.98	-0.18		0.93	0.85	0.95	1.0	0.81	0.94	0.61
Inventory	0.98	-0.16	0.96	0.89	0.95	0.99	0.98	-0.2	0.97	-0.32	0.63	-0.01	0.98	0.61	0.24	0.72	0.97	0.01	0.93		0.9	0.92	0.95	0.94	0.85	0.63
Other Current Assets	0.91	-0.38	0.85	0.89	0.85	0.94	0.95	-0.06	0.86	-0.14	0.61	-0.02	0.92	0.58	0.2	0.75	0.9	0.01	0.85	0.9		0.83	0.86	0.93	0.75	0.38
Other Stockholder Equity	0.95	-0.01	0.95	0.89	0.88	0.91	0.91	-0.06	0.93	-0.45	0.6	0.23	0.94	0.4	0.37	0.77	0.97	-0.19	0.95	0.92	0.83		0.94	0.84	0.87	0.52
Total Liab	0.99	-0.05	0.99	0.92	0.97	0.93	0.94	-0.01	0.98	-0.32	0.71	0.21	0.98	0.39	0.34	0.86	0.99	-0.19	1.0	0.95	0.86	0.94		0.83	0.94	0.65
Property Plant And Equipment Gross	0.9	-0.38	0.84	0.84	0.85	0.97	0.96	-0.31	0.87	-0.31	0.62	-0.15	0.91	0.68	0.14	0.57	0.89	0.11	0.81	0.94	0.93	0.84	0.83		0.68	0.44
Total Current Assets	0.91	0.19	0.92	0.88	0.88	0.83	0.82	0.06	0.88	-0.23	0.63	0.43	0.89	0.22	0.48	0.9	0.9	-0.18	0.94	0.85	0.75	0.87	0.94	0.68		0.61
Short Term Debt	0.62	0.26	0.68	0.5	0.75	0.54	0.53	-0.29	0.7	-0.2	0.43	-0.08	0.61	0.23	-0.09	0.47	0.58	-0.23	0.61	0.63	0.38	0.52	0.65	0.44	0.61

Click cells to compare fundamentals

Takeda Pharmaceutical Account Relationship Matchups

Takeda Pharmaceutical balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	12.8T	12.9T	13.2T	14.0T	15.1T	15.9T
Common Stock Shares Outstanding	1.6B	1.6B	1.6B	1.6B	1.6B	1.3B
Short Long Term Debt Total	5.1T	4.6T	4.3T	4.4T	5.5T	5.7T
Other Current Liab	682.3B	1.3T	1.4T	1.5T	1.1T	1.2T
Total Current Liabilities	2.2T	1.8T	2.1T	2.5T	2.3T	2.4T
Total Stockholder Equity	4.7T	5.2T	5.7T	6.4T	7.3T	7.6T
Property Plant And Equipment Net	1.4T	1.5T	1.6T	1.7T	2.0T	2.1T
Current Deferred Revenue	119.5B	588.0B	616.5B	109.9B	126.4B	120.1B
Net Debt	4.5T	3.7T	3.5T	3.8T	5.3T	5.5T
Retained Earnings	1.4T	1.5T	1.5T	1.5T	1.4T	1.4T
Accounts Payable	318.8B	232.1B	295.9B	307.5B	320.0B	187.0B
Cash	637.6B	966.2B	849.7B	533.5B	205.2B	194.9B
Non Current Assets Total	10.4T	10.2T	10.6T	11.6T	12.6T	13.2T
Non Currrent Assets Other	103.8B	100.3B	82.6B	63.3B	785.9B	825.1B
Cash And Short Term Investments	653.4B	1.0T	875B	553.7B	457.8B	722.1B
Net Receivables	784.9B	812.7B	724.4B	681.7B	697.6B	549.4B
Common Stock Total Equity	168.7B	1.6T	1.7T	1.7T	1.9T	2.0T
Short Term Investments	15.8B	36.6B	25.3B	20.2B	252.6B	143.0B
Liabilities And Stockholders Equity	12.8T	12.9T	13.2T	14.0T	15.1T	15.9T
Non Current Liabilities Total	5.9T	6.0T	5.3T	5.1T	5.5T	5.8T
Inventory	759.6B	753.9B	853.2B	986.5B	1.2T	1.3T
Other Current Assets	114.2B	180.1B	166.4B	196.3B	193.3B	203.0B
Other Stockholder Equity	1.6T	1.6T	1.6T	1.6T	1.7T	1.8T
Total Liab	8.1T	7.7T	7.5T	7.6T	7.8T	8.2T
Property Plant And Equipment Gross	1.4T	1.5T	2.5T	2.7T	3.2T	3.4T
Total Current Assets	2.5T	2.7T	2.6T	2.4T	2.6T	2.0T
Accumulated Other Comprehensive Income	92.6B	366.1B	934.2B	1.5T	2.5T	2.6T
Short Term Debt	586.8B	72.3B	257.9B	399.2B	499.7B	524.7B
Common Stock	1.7T	1.7T	1.7T	1.7T	1.7T	1.8T
Good Will	4.0T	4.0T	4.4T	4.8T	5.4T	5.7T
Intangible Assets	4.2T	3.9T	3.8T	4.3T	4.3T	2.3T
Other Assets	10.4T	454.1B	678.7B	429.3B	493.7B	469.0B
Other Liab	1.1T	831.0B	1.2T	544.1B	625.7B	713.1B
Net Tangible Assets	(3.8T)	(3.5T)	(2.8T)	(2.5T)	(2.3T)	(2.4T)
Long Term Debt	4.5T	4.6T	4.1T	4.0T	4.5T	3.1T
Long Term Investments	369.5B	348.4B	330.1B	378.9B	430.6B	305.1B
Short Long Term Debt	586.8B	22.2B	204.0B	339.6B	367.3B	335.6B
Treasury Stock	(74.4B)	(57.1B)	(87.5B)	(59.6B)	(53.6B)	(56.3B)
Property Plant Equipment	1.4T	1.5T	1.6T	1.7T	1.9T	1.1T
Long Term Debt Total	4.5T	4.6T	4.1T	4.0T	4.6T	3.3T

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:

How To Invest In Takeda

Details

Is Takeda Stock a good investment?

Details

What is Takeda Pharmaceutical's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.049

Dividend Share

192

Earnings Share

0.59

Revenue Per Share

1.4 K

Quarterly Revenue Growth

0.127

The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Takeda Historical Balance Sheet

Takeda Pharmaceutical Inventory

1.27 Trillion

About Takeda Balance Sheet Analysis

Takeda Pharmaceutical Balance Sheet Chart

Total Assets

Common Stock Shares Outstanding

Takeda Pharmaceutical balance sheet Correlations

Takeda Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Takeda Pharmaceutical balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Total Stockholder Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Short Long Term Debt Total	+ 0.99	Total Assets
Common Stock Total Equity	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Assets

Non Currrent Assets Other	- 0.61	Cash
Short Term Investments	- 0.55	Cash
Non Currrent Assets Other	- 0.49	Common Stock Shares Outstanding
Other Stockholder Equity	- 0.45	Retained Earnings
Common Stock Total Equity	- 0.38	Retained Earnings
Property Plant And Equipment Gross	- 0.38	Common Stock Shares Outstanding